<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oruka Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/oruka-therapeutics-inc</link>
<description>Latest news and press releases for Oruka Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 26 Apr 2026 16:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oruka-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a72078dffbe2df10bcce.webp</url>
<title>Oruka Therapeutics, Inc.</title>
<link>https://6ix.com/company/oruka-therapeutics-inc</link>
</image>
<item>
<title>Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-a-trial-on-april-27-2026</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-a-trial-on-april-27-2026</guid>
<pubDate>Sun, 26 Apr 2026 16:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00</description>
</item>
<item>
<title>Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the t</description>
</item>
<item>
<title>Oruka Therapeutics to Participate in Multiple Upcoming Conferences</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-participate-multiple-upcoming-conferences-2026-02-09</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-participate-multiple-upcoming-conferences-2026-02-09</guid>
<pubDate>Mon, 09 Feb 2026 05:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-data-orka-002-and-initiation</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-data-orka-002-and-initiation</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in</description>
</item>
<item>
<title>Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-44th-annual-120000551</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-44th-annual-120000551</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing...</description>
</item>
<item>
<title>Oruka Therapeutics Announces New Board Member and Board Transition</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-new-board-member-and-board-transition-2025-12-11</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-new-board-member-and-board-transition-2025-12-11</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Appoints accomplished commercial leader Chris Martin to its Board of Directors MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc.</description>
</item>
<item>
<title>Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and</description>
</item>
<item>
<title>Oruka Therapeutics to Present at Multiple November Investor Conferences</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-multiple-november-investor-conferences-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-multiple-november-investor-conferences-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces $180 Million Private Placement</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-180-million-private-placement-2025-09-17</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-180-million-private-placement-2025-09-17</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-results-orka-001-2025-09-17</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-results-orka-001-2025-09-17</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could</description>
</item>
<item>
<title>Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented</description>
</item>
<item>
<title>Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-ind-clearance-everlast-phase-2a-trial-orka-001-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-ind-clearance-everlast-phase-2a-trial-orka-001-psoriasis</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further</description>
</item>
<item>
<title>Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-promotion-laura-sandler-chief-operating-officer-2025-07</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-promotion-laura-sandler-chief-operating-officer-2025-07</guid>
<pubDate>Tue, 01 Jul 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-jefferies-global-healthcare-conference-2025-05-21</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-jefferies-global-healthcare-conference-2025-05-21</guid>
<pubDate>Wed, 21 May 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-first-participants-dosed-phase-1-trial-orka-002-its</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-first-participants-dosed-phase-1-trial-orka-002-its</guid>
<pubDate>Tue, 20 May 2025 04:00:00 GMT</pubDate>
<description>Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data</description>
</item>
<item>
<title>Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-first-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-first-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data</description>
</item>
<item>
<title>Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-bank-america-securities-2025-health-care-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-bank-america-securities-2025-health-care-conference-2025</guid>
<pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-preclinical-data-orka-002-2025-american-academy</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-preclinical-data-orka-002-2025-american-academy</guid>
<pubDate>Fri, 07 Mar 2025 05:00:00 GMT</pubDate>
<description>Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three</description>
</item>
<item>
<title>Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Thu, 06 Mar 2025 05:00:00 GMT</pubDate>
<description>ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with</description>
</item>
<item>
<title>Oruka Therapeutics to Present at Multiple March Investor Conferences</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-multiple-march-investor-conferences-2025-02-19</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-multiple-march-investor-conferences-2025-02-19</guid>
<pubDate>Wed, 19 Feb 2025 05:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing</description>
</item>
</channel>
</rss>